According to Oppenheimer, Momenta Pharmaceuticals MNTA holds a positive stance.
Oppenheimer said that on 7/11, the U.S. District Court will begin hearings regarding inequitable conduct claims in the TEVA vs. MYL/Sandoz Copaxone patent litigation. “However, it is possible for the Copaxone patents to be defeated on inequitable conduct grounds, and therefore we have researched the background of important hearing witnesses. We continue to have a positive stance on MNTA, even assuming the company does not successfully defeat TEVA's Copaxone patents.”
Momenta Pharmaceuticals closed on Friday at $20.92.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in